tlooto

Azacitidine.

Jean-Pierre Issa, Hagop M. Kantarjian

2005NATURE REVIEWS DRUG DISCOVERY

Paper details

Journal
NATURE REVIEWS DRUG DISCOVERY
Published
2005
Citations
0
Fields
Medicine

tlooto Summary

Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004, and has been given orphan-drug status.

Abstract

Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.

Citation format

ISSA, Jean-Pierre; KANTARJIAN, Hagop M. Azacitidine. NATURE REVIEWS DRUG DISCOVERY, 2005, Suppl: 6–7.